{
    "clinical_study": {
        "@rank": "139450", 
        "acronym": "WeightPro", 
        "arm_group": [
            {
                "arm_group_label": "control", 
                "arm_group_type": "No Intervention", 
                "description": "standard treatment of IgA nephropathy including ACEI/ARB for blood pressure control (target BP <130/80 mmHg)"
            }, 
            {
                "arm_group_label": "weight reduction", 
                "arm_group_type": "Experimental", 
                "description": "target weight reduction is 3-5% from baseline"
            }
        ], 
        "brief_summary": {
            "textblock": "The study aims to explore the non-pharmacological treatment of IgA nephropathy by weight\n      reduction. The investigators hypothesized that benefits of weight loss may reduce\n      proteinuria."
        }, 
        "brief_title": "The Effects of Weight Reduction in IgA Nephropathy", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Proteinuria", 
        "condition_browse": {
            "mesh_term": [
                "Glomerulonephritis, IGA", 
                "Kidney Diseases", 
                "Proteinuria", 
                "Weight Loss"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective randomized study in adult IgA nephropathy. The investigators enrolled\n      30 patients who have proteinuria exceeds 1 g per day with biopsy proven IgA nephropathy. The\n      experimental arm recieves the non-pharmacological treatment, weight reduction protocol. All\n      patients in this arm must be reduce their body weight in 3-5 % from baseline as protocol.\n      Another arm is control group which recieves standard treatment of IgA nephropathy including\n      ACEIs/ARBs for blood pressure control (target < 130/80 mmHg). The primary outcome is\n      proteinuria level. The secondary outcome is cytokines and inflammatory markers level\n      including interleukin-6, resistin, adiponectin, leptin and monocyte chemoattractant\n      protein-1."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Biopsy-proven IgA nephropathy\n\n          -  body mass index more than 23 Kg/m2\n\n          -  24 hours urine protein more than 1 g\n\n          -  estimated GFR more than 20 ml/min\n\n        Exclusion Criteria:\n\n          -  pregnancy and lactation\n\n          -  rapidly renal function decline\n\n          -  crescent formation in renal biopsy more than 10%"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773382", 
            "org_study_id": "PK8197"
        }, 
        "intervention": {
            "arm_group_label": "weight reduction", 
            "description": "Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal)\nAdvice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks.\nDaily body weight measurement.\nRecord food diary", 
            "intervention_name": "weight  reduction", 
            "intervention_type": "Behavioral", 
            "other_name": "controlled weight reduction program"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 18, 2013", 
        "location": {
            "contact": {
                "email": "piyawankitti@gmail.com", 
                "last_name": "Piyawan Kittiskulnam, M.D.", 
                "phone": "6622564251", 
                "phone_ext": "101"
            }, 
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10330"
                }, 
                "name": "Faculty of medicine, Chulalongkorn university"
            }, 
            "investigator": [
                {
                    "last_name": "Piyawan Kittiskulnam, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Talerngsak Kanjanabuch, Ass. Prof.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Wiwat Chancharoenthana, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of Weight Reduction in Chronic Proteinuric IgA Nephropathy", 
        "overall_official": {
            "affiliation": "Chulalongkorn University", 
            "last_name": "Piyawan Kittiskulnam, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Thailand: Ethical Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The investigators measure amount of 24-hour proteinuria at randomization peroid ( as baseline), first, third and sixth month. Then, investigators calculate the percentage reduction of proteinuria at different time points.", 
            "measure": "Percentage change of 24-hour proteinuria", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773382"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chulalongkorn University", 
            "investigator_full_name": "Talerngsak Kanjanabuch", 
            "investigator_title": "Kidney and metabolic research center, Faculty of medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The investigators measure amount of plasma concentration of IL-6, adiponectin, resistin, leptin, MCP-1 at randomization peroid ( as baseline) and sixth month. Then, investigators calculate the percentage reduction of these cytokines in 6 months peroid.", 
            "measure": "plasma concentration of IL-6, adiponectin, resistin, leptin, MCP-1", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Chulalongkorn University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chulalongkorn University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}